![]() For example, providing PCA data into patient monitoring systems could be used to manage the risk of respiratory depression from the over use of opioids.”įor more information on the CADD ®-Solis ambulatory infusion pump range contact Glen Johnson, NordUK Marketing Manager at Smiths Medical, on 01233 722 100, email or visit References:ġ Wireless communication at launch only available for English language pumpsĢ Model 2100 pumps manufactured before 2011 (Serial Numbers < 10012365) cannot be upgraded to v4. Wireless bi-directional communication sets the foundation for integrating pain management data directly into the patient records in the hospital’s Electronic Medical Records (EMR), saving clinician time charting and increasing documentation accuracy. Jeff Hohn, General Manager & Vice President, Infusion Systems, at Smiths Medical, says: “The new CADD ®-Solis system is a continuation of Smiths Medical’s commitment to advancing patient care and helping to improve outcomes through leading-edge technology. ![]() Turning off wireless communications or the lack of wireless access does not impact pump delivery or data retention. 1Ĭustomers can continue to use previous versions or choose to upgrade any CADD ®-Solis model 2110 pump 2 to CADD ®-Solis v4.1 software using SureLink ® remote support software, while maintaining their existing drug library. Wireless two-way communication with the PharmGuard ® Server software to help increase efficiencies, reduce costs, and improve patient outcomes.The addition of profiles to categorize drug protocols or represent care areas.Longer drug names to eliminate abbreviating or truncating drug names and concentrations.The CADD ®-Solis v4.1 pump enables new features such as: The CADD ®-Solis pump maintains the advantages of an ambulatory pump for patient mobility and also provides a single system that effectively delivers IV PCA, epidurals and peripheral nerve blocks from pump to patient. The CADD ®-Solis v4.1 pump is UL-marked and has full compliance with the latest product standards, including IEC-60601-1 Edition 3.1. Smiths Medical, a leading global medical device manufacturer, has released the CADD ®-Solis ambulatory infusion pump version 4.1 that sets the foundation for wireless communication globally. infusion of ketamine, but is associated with intolerable side effects.CADD®-Solis ambulatory infusion pump version 4.1 The present results show that continuous, spontaneous and evoked pain in patients with post-herpetic neuralgia is reduced by continuous s.c. Other common side-effects were nausea, fatigue and dizziness. Itching and painful indurations at the injection site was the most bothersome side-effect and for this reason 1 patient discontinued treatment after 2 weeks. Assessing the effectiveness of pain control and monitoring the CADD pump and the infusion site. Double checking and documenting the pump settings and totals delivered at change of shift. Allodynia was maximally reduced 59-100% after 1 week infusion of 0.05 mg/kg/h, and wind-up-like pain was maximally reduced 60-100% after 1 week infusion of 0.15 mg/kg/h. Performing the second check of new medication cassettes and verifying pumps settings at set up or after a change. Changes in evoked pain (allodynia and wind-up-like pain) were recorded before change of infusion rate. All the patients reported that ketamine reduced the severity of continuous pain as well as reduced the severity and number of attacks of spontaneous pain. Relief of continuous pain, as evaluated daily by visual analogue scales, was observed at the infusion rate of 0.05 mg/kg/h, but was most marked during infusion of 0.15 mg/kg/h. Ketamine was administered continuously in increasing doses using a portable infusion pump (CADD-PLUS, Pharmacia), and the treatment period for each infusion rate (0.05, 0.075, 0.10, or 0.15 mg/kg/h) was 7 days and nights. Five patients that reported pain relief after acute intravenous injection of ketamine were included in this open prospective study. The effect of continuous subcutaneous (s.c.) infusion of ketamine on nerve injury pain was examined in patients with post-herpetic neuralgia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |